Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 53
Filter
1.
Science ; 242(4884): 1433-7, 1988 Dec 09.
Article in English | MEDLINE | ID: mdl-3144040

ABSTRACT

Potassium channels in neurons are linked by guanine nucleotide binding (G) proteins to numerous neurotransmitter receptors. The ability of Go, the predominant G protein in the brain, to stimulate potassium channels was tested in cell-free membrane patches of hippocampal pyramidal neurons. Four distinct types of potassium channels, which were otherwise quiescent, were activated by both isolated brain G0 and recombinant Go alpha. Hence brain Go can couple diverse brain potassium channels to neurotransmitter receptors.


Subject(s)
GTP-Binding Proteins/pharmacology , Hippocampus/physiology , Potassium Channels/physiology , Recombinant Proteins/pharmacology , Adenylyl Imidodiphosphate/pharmacology , Animals , Cattle , Electric Conductivity , In Vitro Techniques , Kinetics , Macromolecular Substances , Membrane Potentials/drug effects , Potassium Channels/drug effects , Pyramidal Tracts/physiology , Rats
2.
Science ; 243(4892): 804-7, 1989 Feb 10.
Article in English | MEDLINE | ID: mdl-2536957

ABSTRACT

Signal transducing guanine nucleotide binding (G) proteins are heterotrimers with different alpha subunits that confer specificity for interactions with receptors and effectors. Eight to ten such G proteins couple a large number of receptors for hormones and neurotransmitters to at least eight different effectors. Although one G protein can interact with several receptors, a given G protein was thought to interact with but one effector. The recent finding that voltage-gated calcium channels are stimulated by purified Gs, which stimulates adenylyl cyclase, challenged this concept. However, purified Gs may have four distinct alpha-subunit polypeptides, produced by alternative splicing of messenger RNA. By using recombinant DNA techniques, three of the splice variants were synthesized in Escherichia coli and each variant was shown to stimulate both adenylyl cyclase and calcium channels. Thus, a single G protein alpha subunit may regulate more than one effector function.


Subject(s)
Adenylyl Cyclases/physiology , Calcium Channels/physiology , GTP-Binding Proteins/genetics , Animals , GTP-Binding Proteins/physiology , GTP-Binding Proteins/ultrastructure , In Vitro Techniques , Macromolecular Substances , RNA Splicing , Structure-Activity Relationship
3.
Oncoimmunology ; 6(11): e1356151, 2017.
Article in English | MEDLINE | ID: mdl-29147611

ABSTRACT

Autophagy is usually a pro-survival mechanism in cancer cells, especially in the course of chemotherapy, thus autophagy inhibition may enhance the chemotherapy-mediated anti-cancer effect. However, since autophagy is strongly involved in the immunogenicity of cell death by promoting ATP release, its inhibition may reduce the immune response against tumors, negatively influencing the overall outcome of chemotherapy. In this study, we evaluated the in vitro and in vivo anti-cancer effect of curcumin (CUR) against Her2/neu overexpressing breast cancer cells (TUBO) in the presence or in the absence of the autophagy inhibitor chloroquine (CQ). We found that TUBO cell death induced by CUR was increased in vitro by CQ and slightly in vivo in nude mice. Conversely, CQ counteracted the Cur cytotoxic effect in immune competent mice, as demonstrated by the lack of in vivo tumor regression and the reduction of overall mice survival as compared with CUR-treated mice. Immunohistochemistry analysis revealed the presence of a remarkable FoxP3 T cell infiltrate within the tumors in CUR/CQ treated mice and a reduction of T cytotoxic cells, as compared with single CUR treatment. These findings suggest that autophagy is important to elicit anti-tumor immune response and that autophagy inhibition by CQ reduces such response also by recruiting T regulatory (Treg) cells in the tumor microenvironment that may be pro-tumorigenic and might counteract CUR-mediated anti-cancer effects.

4.
Circulation ; 103(19): 2395-401, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11352890

ABSTRACT

BACKGROUND: Patients with transfusional iron overload may develop a life-limiting cardiomyopathy. The sensitivity of lipid-metabolizing enzymes to peroxidative injury, as well as the reported effects of arachidonic acid (AA) and metabolites on cardiac rhythm, led us to hypothesize that iron-overloaded cardiomyocytes display alterations in the release of AA and prostaglandins. METHODS AND RESULTS: Neonatal rat ventricular myocytes (NRVMs) cultured for 72 hours in the presence of 80 microgram/mL ferric ammonium citrate displayed an increased rate of AA release, both under resting conditions and after stimulation with agonists such as [Sar(1)]Ang II. Although iron treatment did not affect overall incorporation of [(3)H]AA into NRVM phospholipids, it caused a 2-fold increase in the distribution of precursor in phosphatidylcholine species, with a proportional decrease in phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine. Increased release of AA in iron-overloaded NRVMs was reduced by the diacylglycerol lipase inhibitor RHC80267 but was largely insensitive to inhibitors of phospholipases A(2) and C. Iron-overloaded cardiomyocytes also displayed increased production of eicosanoids and induction of cyclooxygenase-2 after stimulation with interleukin-1alpha. CONCLUSIONS: Iron overload enhances AA release and incorporation of AA into phosphatidylcholine, as well as cyclooxygenase-2 induction and eicosanoid production, in NRVMS: The effects of AA and metabolites on cardiomyocyte rhythmicity suggest a causal connection between these signals and electromechanical alterations in iron-overload-induced cardiomyopathy.


Subject(s)
Arachidonic Acid/metabolism , Eicosanoids/metabolism , Heart Ventricles/drug effects , Iron/pharmacology , Angiotensin II/analogs & derivatives , Angiotensin II/pharmacology , Animals , Animals, Newborn , Cells, Cultured , Dose-Response Relationship, Drug , Female , Ferric Compounds/pharmacology , Heart Ventricles/cytology , Heart Ventricles/metabolism , Humans , Iron/metabolism , Phospholipids/metabolism , Pregnancy , Prostaglandins/metabolism , Quaternary Ammonium Compounds/pharmacology , Rats , Rats, Sprague-Dawley , Time Factors , Tritium
5.
Mol Endocrinol ; 1(7): 472-81, 1987 Jul.
Article in English | MEDLINE | ID: mdl-3155263

ABSTRACT

ADP ribosylation of membranes by pertussis toxin (PT) and cholera toxin (CT) was studied as a function of addition of ATP, various guanine nucleotides, Mg2+, and inorganic phosphate (Pi). ADP ribosylation of a 40 kilodalton (kDa) band by PT is markedly enhanced by ATP and GTP and is strongly inhibited by Pi or Mg2+. GTP analogs (GTP gamma S and GMP-adenyl-5'-yl imidodiphosphate) were less effective. In contrast, ADP ribosylation of two substrates for CT (of 42 and 50 kDa) is stimulated by Pi, Mg2+, and GTP or GTP analogs such as GTP gamma S, but is unaffected by ATP. These stimulatory conditions correlate well with GTP-mediated activation of stimulated nucleotide-binding regulatory component of adenyl cyclase. Optimal conditions for ADP ribosylation by PT do not correlate simply with conditions thought to lead to stabilization of an inactive form of inhibitory nucleotide-binding regulatory component of adenyl cyclase (Gi) or Gi-like protein; rather, the data suggest the involvement of both a stimulatory nucleotide site on PT (positively affected by either ATP or GTP) and a stabilizing site on the PT substrate (affected by GDP, GDP beta S, or GTP). Treatment of membranes with Lubrol PX increased ADP ribosylation by PT by as much as 25- to 30-fold, but inhibited the action of CT. Using defined conditions for ADP ribosylation by PT and CT, distinct labeling patterns were observed in thyroid, brain, corpus luteum, liver, heart, and erythrocytes membranes. All membranes were more intensely labeled by PT rather than CT.


Subject(s)
Adenosine Diphosphate Ribose/metabolism , Adenylate Cyclase Toxin , Cholera Toxin/pharmacology , GTP-Binding Proteins/metabolism , Pertussis Toxin , Thyroid Gland/drug effects , Virulence Factors, Bordetella/pharmacology , Animals , Cattle , Detergents , Guanine Nucleotides/pharmacology , In Vitro Techniques , Magnesium/pharmacology , Membranes/drug effects , Membranes/metabolism , Phosphorus/pharmacology , Polidocanol , Polyethylene Glycols , Thyroid Gland/metabolism
6.
Endocrinology ; 138(10): 4109-22, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9322919

ABSTRACT

The vasopressin (AVP) V3 pituitary receptor (V3R) is a G protein-coupled corticotropic phenotypic marker that is overexpressed in ACTH-hypersecreting tumors. Studies of the agonist/antagonist binding profile and signal transduction pathways linked to the human V3R have been limited because of the scarcity of this protein. To define the signals activated by V3Rs and the eventual changes triggered by developmental or pathological receptor regulation, we developed Chinese hamster ovary (CHO)-V3 cells stably expressing low, medium, or high levels of human V3Rs (binding capacity, <10, 10-25, and 25-100 pmol/mg, respectively). The affinity of the V3R for 21 peptide and nonpeptide AVP analogs was clearly distinct from that exhibited by the human V1R and V2R. AVP triggered stimulation of phospholipase C in CHO-V3 cells (partially sensitive to treatment with pertussis toxin) with a potency directly proportional to receptor density. V3R-mediated arachidonic acid release also was also sensitive to pertussis toxin and more efficacious in cells exhibiting medium than in those with high receptor density. AVP also stimulated the pertussis toxin-insensitive uptake of [3H]thymidine in CHO-V3 cells. The concentration-response curves for this effect were monophasic in cells expressing low and medium levels of V3Rs; on the contrary, a biphasic curve was observed in cells with high V3R density. Coupling of V3R to increased production of cAMP was only observed in CHOV3 high cells, suggesting a negative relationship between increased cAMP production and DNA synthesis. Activation of mitogen-activated protein kinases by V3R was pertussis toxin insensitive, but was dependent on activation of phospholipase C and protein kinase C; both the level and duration of activation were a function of the receptor density. Thus, the human V3R has a pharmacological profile clearly distinct from that of the human V1R and V2R and activates several signaling pathways via different G proteins, depending on the level of receptor expression. The increased synthesis of DNA and cAMP levels observed in cells expressing medium and high levels of V3Rs, respectively, may represent important events in the tumorigenesis of corticotroph cells.


Subject(s)
Pituitary Gland/chemistry , Receptors, Vasopressin/analysis , Receptors, Vasopressin/metabolism , Signal Transduction/physiology , Animals , Arachidonic Acid/metabolism , Base Sequence , CHO Cells , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Division/physiology , Cricetinae , Cyclic AMP/metabolism , Cyclic AMP/physiology , DNA/analysis , DNA/genetics , DNA/metabolism , Dose-Response Relationship, Drug , Female , Humans , Ligands , Pertussis Toxin , Phenotype , Phosphorylation , Pituitary Gland/cytology , Protein Binding , Protein Kinase C/analysis , Protein Kinase C/physiology , Receptors, Vasopressin/physiology , Thymidine/metabolism , Tritium , Type C Phospholipases/analysis , Type C Phospholipases/physiology , Virulence Factors, Bordetella/pharmacology
7.
FEBS Lett ; 220(1): 187-92, 1987 Aug 10.
Article in English | MEDLINE | ID: mdl-2440724

ABSTRACT

The amino acid sequence and composition of alpha-subunits of signal transducing G proteins of the same kind appear to vary by no more than 2% from species to species. Here we isolated a human liver cDNA using an oligonucleotide complementary to the sequences encoding the pertussis toxin (PTX) ADP-ribosylation site of the alpha-subunit of the rat brain G protein called Gi. Its open reading frame characterizes it as an alpha i-type cDNA--as opposed to alpha o-type--but predicts an amino acid composition that differs by 7% and 14%, respectively, from two other human alpha i-type molecules. Together with human brain alpha i (type-1) and human monocyte alpha i (type-2), the new human liver alpha i cDNA (type-3) forms parts of a family of alpha i molecules. Type-3 alpha i cDNA hybridizes to a approximately 3.6 kilobase long mRNA and type-2 alpha i cDNA hybridizes to an mRNA species of approximately 2.7 kilobases. This indicates that the human genome has at least three non-allellic genes encoding non-alpha o-type PTX substrates and provides structural evidence for the hypothesis that distinct effector systems are regulated by similar but nevertheless distinct PTX substrates.


Subject(s)
Nerve Tissue Proteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Brain Chemistry , Cattle , DNA/analysis , Female , Humans , Liver/analysis , Male , Mice , Monocytes/analysis , Nerve Tissue Proteins/analysis , Nucleic Acid Hybridization , Ovary/analysis , Pertussis Toxin , RNA/analysis , Rats , Species Specificity , Testis/analysis , Virulence Factors, Bordetella/genetics
8.
FEBS Lett ; 206(1): 36-42, 1986 Sep 29.
Article in English | MEDLINE | ID: mdl-3093273

ABSTRACT

Two DNA molecules complementary to human liver mRNA coding for the alpha-subunit of the stimulatory regulatory component Gs of adenylyl cyclase were cloned. One of the two forms is a full-length cDNA of 1614 nucleotides plus a poly(A) tail of 59 nucleotides. The deduced sequence of 394 amino acids encoded by its open reading frame is essentially identical to that of the alpha-subunits of Gs identified by molecular cloning from bovine adrenals, bovine brain and rat brain. Two independent clones of the other type of cDNA were isolated. Both were incomplete, beginning within the open reading frame coding for the alpha s polypeptide. One codes for amino acids 5 through 394 and the other for amino acids 48 through 394 of the above described cDNA of 1614 nucleotides, and both have the identical 3'-untranslated sequence. They differ from the first cDNA, however, in that they lack a stretch of 42 nucleotides (numbers 214 through 255) and have nucleotides 213 (G) and 256 (G) replaced with C and A, respectively. This results in a predicted amino acid composition of another alpha-subunit of Gs that is shorter by 14 amino acids and contains two substitutions (Asp for Glu and Ser for Gly) at the interface between the deletion and the unchanged sequence. We call the smaller subunit alpha s1 and the larger alpha s2. This is the first demonstration of a structural heterogeneity in alpha s subunits that is due to a difference in amino acid sequence.


Subject(s)
Adenylyl Cyclases/genetics , DNA/genetics , GTP-Binding Proteins/genetics , Liver/enzymology , Amino Acid Sequence , Base Sequence , Cloning, Molecular , Humans , Nucleic Acid Hybridization , RNA, Messenger/genetics
9.
Prog Brain Res ; 119: 147-61, 1998.
Article in English | MEDLINE | ID: mdl-10074787

ABSTRACT

Vasopressin (VP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by stimulation of specific G protein-coupled receptors (GPCRs) currently classified into V1-vascular (V1R), V2-renal (V2R) and V3-pituitary (V3R) VP receptors and OT receptors (OTR). The recent cloning of the different members of the VP/OT family of receptors now allows the extensive characterization of the molecular determinants involved in ligand binding and signal transduction pathways coupled to a given VP/OT receptor subtype in stably transfected mammalian cell lines. In this article, we review the present knowledge of the signal transduction pathways coupled to the different VP/OT receptor subtypes and we present new observations derived from the study of each human VP or OT receptor subtype stably expressed in CHO cells.


Subject(s)
Receptors, Oxytocin/physiology , Receptors, Vasopressin/physiology , Signal Transduction/physiology , Animals , CHO Cells , Cricetinae , Endothelium, Vascular/chemistry , Endothelium, Vascular/physiology , Humans , Kidney/chemistry , Kidney/physiology , Pituitary Gland/chemistry , Pituitary Gland/physiology
10.
J Appl Physiol (1985) ; 89(1): 72-80, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10904037

ABSTRACT

Contraction-induced respiratory muscle fatigue and sepsis-related reductions in respiratory muscle force-generating capacity are mediated, at least in part, by reactive oxygen species (ROS). The subcellular sources and mechanisms of generation of ROS in these conditions are incompletely understood. We postulated that the physiological changes associated with muscle contraction (i.e., increases in calcium and ADP concentration) stimulate mitochondrial generation of ROS by a phospholipase A(2) (PLA(2))-modulated process and that sepsis enhances muscle generation of ROS by upregulating PLA(2) activity. To test these hypotheses, we examined H(2)O(2) generation by diaphragm mitochondria isolated from saline-treated control and endotoxin-treated septic animals in the presence and absence of calcium and ADP; we also assessed the effect of PLA(2) inhibitors on H(2)O(2) formation. We found that 1) calcium and ADP stimulated H(2)O(2) formation by diaphragm mitochondria from both control and septic animals; 2) mitochondria from septic animals demonstrated substantially higher H(2)O(2) formation than mitochondria from control animals under basal, calcium-stimulated, and ADP-stimulated conditions; and 3) inhibitors of 14-kDa PLA(2) blocked the enhanced H(2)O(2) generation in all conditions. We also found that administration of arachidonic acid (the principal metabolic product of PLA(2) activation) increased mitochondrial H(2)O(2) formation by interacting with complex I of the electron transport chain. These data suggest that diaphragm mitochondrial ROS formation during contraction and sepsis may be critically dependent on PLA(2) activation.


Subject(s)
Diaphragm/metabolism , Mitochondria/enzymology , Phospholipases A/metabolism , Reactive Oxygen Species/metabolism , Adenosine Diphosphate/metabolism , Adenosine Triphosphate/pharmacology , Animals , Arachidonic Acid/pharmacology , Calcium/pharmacology , Cyanides/pharmacology , Electron Transport Complex I , Electron Transport Complex IV/metabolism , Enzyme Inhibitors/pharmacology , Hydrogen Peroxide/metabolism , Malates/metabolism , Male , Melitten/pharmacology , Mitochondria/drug effects , NADH, NADPH Oxidoreductases/metabolism , NADPH Oxidases/antagonists & inhibitors , NADPH Oxidases/metabolism , Onium Compounds/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Phospholipases A/antagonists & inhibitors , Pyruvic Acid/metabolism , Rats , Rats, Inbred Strains , Rotenone/pharmacology , Sepsis/metabolism , Terpenes/pharmacology , Uncoupling Agents/pharmacology
11.
Adv Exp Med Biol ; 449: 251-76, 1998.
Article in English | MEDLINE | ID: mdl-10026814

ABSTRACT

Vasopressin (AVP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by activation of specific G protein-coupled receptors (GPCRs) currently classified into V1-vascular (V1R), V2-renal (V2R) and V3-pituitary (V3R) AVP receptors and OT receptors (OTR). The cloning of the different members of the AVP/OT family of receptors now allows the extensive molecular pharmacological characterization of a single AVP/OT receptor subtype in stably transfected mammalian cell lines. The human V1-vascular (CHO-V1), V2-renal (CHO-V2), V3-pituitary (CHO-V3) and oxytocin (CHO-OT) receptors stably expressed in CHO cells display distinct binding profiles for 18 peptide and 5 nonpeptide AVP/OT analogs. Several peptide and nonpeptide compounds have a greater affinity for the V1R than AVP itself. V2R peptide agonists and antagonists tend to be non-selective ligands whereas nonpeptide V2R antagonists are potent and subtype-selective. None of the 22 AVP/OT analogs tested has a better affinity for the human V3R than AVP itself. Several peptide antagonists do not select well between V1R and OTR. These results underscore the need for developing specific and potent analogs interacting specifically with a given human AVP/OT receptor subtype.


Subject(s)
Arginine Vasopressin/pharmacology , Hormone Antagonists/pharmacology , Oxytocin/pharmacology , Receptors, Oxytocin/physiology , Receptors, Vasopressin/genetics , Receptors, Vasopressin/physiology , Animals , Arginine Vasopressin/antagonists & inhibitors , CHO Cells , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Division/drug effects , Cricetinae , Cyclic AMP/metabolism , DNA/biosynthesis , DNA, Complementary , Gene Library , Humans , Kidney/metabolism , Liver/metabolism , Models, Biological , Open Reading Frames , Phosphorylation , Receptors, Oxytocin/drug effects , Receptors, Oxytocin/genetics , Receptors, Vasopressin/drug effects , Recombinant Proteins/metabolism , Signal Transduction , Transfection
12.
Medicina (B Aires) ; 49(6): 600-2, 1989.
Article in Spanish | MEDLINE | ID: mdl-2487433

ABSTRACT

Cryptococcus neoformans is an infrequent but important cause of severe disease in immunodepressed patients, especially in those with AIDS. We refer the case of a 45 year old patient with clinical, epidemiological and serological patterns of HIV-induced infection in the course of which the patient suffered a subacute neurologic syndrome with fatal evolution. The diagnosis was made by isolation of Cryptococcus neoformans in CSF and in palpable lymph nodes by fine-needle aspiration biopsy. Cryptococcal antigen titer of CSF was 1:2560. Treatment was standardized in the administration of amphotericin B (0.3 mg/kg/day) and 5-fluocytosine (150 mg/kg/day) for a period of six weeks. Factors that suggested poor prognosis were: a positive india ink preparation before treatment, a high initial CSF antigen titer, low CSF leukocyte count and the presence of Cryptococcus neoformans at an extraneural site. Since diagnosis of cryptococcosis was made when prominent localizing symptoms and signs were found, an intensive culture and serologic screening would be necessary in every patient with AIDS in order to establish an earlier diagnosis.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Cryptococcosis/complications , Opportunistic Infections/complications , Humans , Male , Middle Aged , Prognosis
18.
J Biol Chem ; 267(36): 25966-75, 1992 Dec 25.
Article in English | MEDLINE | ID: mdl-1464609

ABSTRACT

We studied the regulation of arachidonic acid (AA) release by guanosine 5'-O-(3-thiotriphosphate (GTP gamma S) and Ca2+ in electropermeabilized HL60 granulocytes. Stimulation of AA release by GTP gamma S and Ca2+ was mediated by phospholipase A2 (PLA2) and required the presence of MgATP (EC50: 100-250 microM). The nucleotide effects were Ca(2+)-dependent (maximal effects detected at 1 microM free cation). UTP and ATP gamma S, which stimulate AA release in intact HL60 granulocytes with potencies and efficacies similar to those of ATP, were ineffective in supporting the effects of GTP gamma S in electropermeabilized cells. Pretreatment with pertussis toxin affected stimulation of AA release by ATP in intact cell, without altering the nucleotide effects in permeabilized cells. We observed the protein kinase C-dependent phosphorylation of PLA2 in permeabilized HL60 granulocytes, together with a correlation between the effects of phorbol esters and staurosporine on this reaction and on AA release. ATP-independent activation of PLA2 by GTP gamma S and/or Ca2+ was measured in subcellular fractions prepared from HL60 granulocytes. These data appear consistent with a model in which PLA2 activity in resting HL60 granulocytes is subjected to an inhibitory constraint that prevents its activation by Ca2+ and G-proteins. Removal of this constraint, either by the protein kinase C-dependent phosphorylation of the enzyme in vivo or physical disruption of the regulatory assembly (e.g. by N2 cavitation), allows its activation by Ca2+ and G-proteins.


Subject(s)
Arachidonic Acid/metabolism , Calcium/pharmacology , GTP-Binding Proteins/metabolism , Granulocytes/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Adenosine Triphosphate/pharmacology , Adenylyl Imidodiphosphate/pharmacology , Alkaloids/pharmacology , Egtazic Acid/pharmacology , Enzyme Activation , Granulocytes/drug effects , Homeostasis , Humans , Isoflurophate/pharmacology , Kinetics , Leukemia, Promyelocytic, Acute , Models, Biological , Pertussis Toxin , Phosphorylation , Protein Kinase C/antagonists & inhibitors , Ribonucleotides/pharmacology , Staurosporine , Tumor Cells, Cultured , Virulence Factors, Bordetella/pharmacology
19.
Int J Pept Protein Res ; 19(2): 181-6, 1982 Feb.
Article in English | MEDLINE | ID: mdl-6288584

ABSTRACT

Iodinated bovine growth hormone, containing no more than 1 g-atom of iodine per mole of hormone is generally used as a tracer in studies related to the action and metabolism of the hormone. This derivative was tested in different biological and immunological systems in which the hormone is known to be active. The iodinated derivative was almost indistinguishable in its properties from the native hormone when it was examined by the following criteria: body growth promoting activity, rat liver uptake in vivo, binding to rabbit liver microsomes and primary antigen-antibody interactions. Micro-complement fixation experiments suggested that the iodination produces minor alterations in the affinity of some antigenic determinants.


Subject(s)
Growth Hormone/analogs & derivatives , Receptors, Cell Surface/metabolism , Animals , Biological Assay , Biological Transport , Body Weight/drug effects , Cattle , Complement Fixation Tests , Erythrocytes/drug effects , Growth Hormone/metabolism , Hemagglutination , Hypophysectomy , Iodine Radioisotopes , Kinetics , Liver/metabolism , Microsomes, Liver/metabolism , Rabbits , Rats , Receptors, Somatotropin
20.
J Biol Chem ; 267(10): 6602-10, 1992 Apr 05.
Article in English | MEDLINE | ID: mdl-1313016

ABSTRACT

ATP promoted biphasic effects on both basal and fMLP-stimulated arachidonic acid (AA) release in neutrophil-like HL60 cells: stimulation in the micromolar range (EC50 = 3.2 +/- 0.9 microM) and inhibition at higher concentrations (EC50 = 90 +/- 11 microM). ATP also inhibited UTP- and platelet activating factor-stimulated AA release. Only stimulatory effects of ATP on basal or fMLP-stimulated phospholipase C were observed. The inhibitory effect of ATP on AA release was not due to reacylation of released AA, chelation of extracellular Ca2+, cell permeabilization, or changes in the rise of [Ca2+]i induced by agonist. The inhibition was rapid, being detected within 5-15 s. The inhibitory effect of ATP on fMLP-stimulated AA release could be desensitized by pretreatment of the cells with 2 mM ATP, but not 20 microM ATP, the concentration that resulted in maximal release of AA and inositol phosphates. The inhibition by ATP was neither dependent on generation of adenosine by ATP hydrolysis nor the result of direct interaction of ATP with P1 purinergic receptors. Among other nucleotides tested (CTP, GTP, ITP, TTP, XTP, adenosine 5'-(beta,gamma-methylene)triphosphate (AMP-PCP), adenyl-5'-yl imidodiphosphate (AMP-P(NH)P), ADP, adenosine 5'-O-(3-thiotriphosphate) (ATP gamma S), and UTP), only UTP and ATP gamma S displayed biphasic effects with potencies and efficacies almost identical to those of ATP. The other nucleotides only exhibited stimulatory effects (EC50 = 60-300 microM). The results are consistent with a model of dual regulation of AA release by two distinct subtypes of P2U receptors in HL60 cells.


Subject(s)
Arachidonic Acid/metabolism , Bucladesine/pharmacology , Cell Differentiation/drug effects , Receptors, Purinergic/metabolism , Adenosine Triphosphate/metabolism , Adenosine Triphosphate/pharmacology , Cell Line , Cytidine Triphosphate/pharmacology , Enzyme Activation , Guanosine Triphosphate/pharmacology , Hydrolysis , Inositol Phosphates/metabolism , Microscopy, Fluorescence , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Purine Nucleotides/pharmacology , Pyrimidine Nucleotides/pharmacology , Second Messenger Systems , Type C Phospholipases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL